Loading...
Intas Pharmaceuticals Limited — Anastrozole Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #1 for Anastrozole · $10.4M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #1 Indian exporter of Anastrozole with $10.4M in export value and 209 verified shipments. Intas Pharmaceuticals Limited holds a 9.4% market share in Anastrozole exports across 13 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $2.0M | 99 | 76.3% |
| UNITED KINGDOM | $246.6K | 27 | 9.5% |
| SOUTH AFRICA | $90.7K | 9 | 3.5% |
| CANADA | $85.0K | 10 | 3.3% |
| AUSTRALIA | $82.1K | 10 | 3.2% |
| GREECE | $37.7K | 9 | 1.5% |
| JAMAICA | $31.0K | 9 | 1.2% |
| NETHERLANDS | $18.2K | 13 | 0.7% |
| PERU | $17.8K | 1 | 0.7% |
| TRINIDAD TOBAGO | $2.7K | 1 | 0.1% |
Intas Pharmaceuticals Limited exports Anastrozole to 13 countries. The largest destination is UNITED STATES accounting for 76.3% of Intas Pharmaceuticals Limited's Anastrozole shipments, followed by UNITED KINGDOM (9.5%) and SOUTH AFRICA (3.5%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCES SERVICES,LLC | UNITED STATES | $1.2M | 54 |
| EVERSANA LIFE SCIENCES SERVICES LLC | UNITED STATES | $498.4K | 23 |
| ACCORD UK | UNITED KINGDOM | $246.6K | 20 |
| TO THE ORDER | MALTA | $172.6K | 24 |
| ACCORD HEALTHCARE INC. | CANADA | $75.9K | 5 |
India exported $25.8M worth of Anastrozole through 2,238 shipments from 158 suppliers to 99 countries, serving 387 buyers globally. Intas Pharmaceuticals Limited contributes $10.4M to this total, accounting for 9.4% of India's Anastrozole exports. Intas Pharmaceuticals Limited ships Anastrozole to 13 countries through 31 buyers.
Intas Pharmaceuticals Limited's average Anastrozole shipment value is $50.0K per consignment, based on 209 shipments totaling $10.4M. The largest destination is UNITED STATES (76.3% of Intas Pharmaceuticals Limited's Anastrozole exports).
Intas Pharmaceuticals Limited ranks #1 among 158 Indian Anastrozole exporters with a 9.4% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($10.4M), ZYDUS LIFESCIENCES LIMITED ($3.6M), EUGIA PHARMA SPECIALITIES LIMITED ($3.5M). Intas Pharmaceuticals Limited processed 209 shipments to 13 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHR DRUGS&MEDI ANASTROZOLE TABLETS 1 MG | $410.3K | 14 |
| PHARMA DRUGS & MEDI ANASTROZOLE TABLETS | $179.5K | 14 |
| PHR DRUGS & MEDI ANASTROZOLE TABLETS 1 M | $158.1K | 4 |
| PHARMA DRUGS MEDI ANASTROZOLE TABLETS 1 MG AS PER INVOICE | $144.4K | 9 |
| PHR DRUGS MEDI ANASTROZOLE TABLETS 1 MG EACH FILM COATED TABLET CONTAINS ANASTROZOLE USP 1MG AS PER INVOICE | $138.0K | 4 |
| PHARMA DRUGS MEDI ANASTROZOLE 1MG 2X14T G1 ACCORD UK AS PER INVOICE | $126.6K | 13 |
| PHARMA DRUGS & MEDI ANASTROZOLE TABLETS 1 MG AS PER INVOICE | $103.4K | 6 |
| PHARMA DRUGS & MEDI ANASTROZOLE TABLETS1 MG AS PER INVOICE | $96.8K | 9 |
What Intas Pharmaceuticals Limited must comply with to export Anastrozole to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED ★ | $10.4M | 209 | 13 | $50.0K |
| 2 | ZYDUS LIFESCIENCES LIMITED | $3.6M | 111 | 3 | $32.4K |
| 3 | EUGIA PHARMA SPECIALITIES LIMITED | $3.5M | 116 | 6 | $30.4K |
Intas Pharmaceuticals Limited ranks #1 among 158 Indian Anastrozole exporters. Average shipment value of $50.0K compared to the market average of $163.1K. The closest competitors by value are ZYDUS LIFESCIENCES LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 465 | 20.8% |
| SAHAR AIR | 391 | 17.5% |
| DELHI AIR CARGO ACC (INDEL4) | 280 | 12.5% |
| DELHI AIR | 167 | 7.5% |
| MUNDRA SEA | 90 | 4.0% |
| Bombay Air | 86 | 3.8% |
| HYDERABAD AIR | 75 | 3.4% |
| MUNDRA SEA (INMUN1) | 70 | 3.1% |
Intas Pharmaceuticals Limited also exports these advanced oncology products. Each links to the detailed product page.
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Anastrozole, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Anastrozole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Anastrozole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
| ALPHAPHARM PTY LIMITED |
| AUSTRALIA |
| $68.7K |
| 9 |
| EVERSANA LIFE SCIENCES SERVICESLLC | UNITED STATES | $58.9K | 7 |
| ACCORD HEALTHCARE C/O QESTMED (PTY) | SOUTH AFRICA | $52.0K | 2 |
| SIVEM PHARMACEUTICALS | UNITED STATES | $39.6K | 2 |
| TO HE ORDER | UNITED STATES | $35.6K | 3 |
Intas Pharmaceuticals Limited supplies Anastrozole to 31 buyers globally. The largest buyer is EVERSANA LIFE SCIENCES SERVICES,LLC (UNITED STATES), followed by EVERSANA LIFE SCIENCES SERVICES LLC (UNITED STATES) and ACCORD UK (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| PHARMACEUTICAL DRUGS AND MEDICINE ANASTROZOLE TABLETS 1 MG AS PER INVOICE | $93.2K | 8 |
| PHA.DRU & MEDI, ANASTROZOLE TABLETS 1 MG | $84.9K | 2 |
Intas Pharmaceuticals Limited exports 80 distinct Anastrozole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHR DRUGS&MEDI ANASTROZOLE TABLETS 1 MG with 14 shipments worth $410.3K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 99+ countries, 387+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Anastrozole. For current shipment-level data, contact TransData Nexus.